Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07667868
PHASE1
A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma
Sponsor: BrightPath Biotherapeutics Co., Ltd.
View on ClinicalTrials.gov
Summary
The purpose of this study is to find out if BP2202 is safe and can treat participants with Relapsed/Refractory Multiple Myeloma.
Official title: A Phase I, Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients[尚小1.1] With Relapsed/Refractory Multiple Myeloma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2026-10-01
Completion Date
2043-12-31
Last Updated
2026-06-25
Healthy Volunteers
No
Interventions
BIOLOGICAL
BP2202
Intravenous infusion